Literature DB >> 15858182

A unifying mutation in chronic myeloproliferative disorders.

John M Goldman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15858182     DOI： 10.1056/NEJMp058083

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7.

Authors:  Stefan Fröhling; Daniel B Lipka; Sabine Kayser; Claudia Scholl; Richard F Schlenk; Hartmut Döhner; D Gary Gilliland; Ross L Levine; Konstanze Döhner
Journal:  Blood       Date:  2006-02-01       Impact factor: 22.113

2.  Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.

Authors:  Elizabeth O Hexner; John Mascarenhas; Josef Prchal; Gail J Roboz; Maria R Baer; Ellen K Ritchie; David Leibowitz; Erin P Demakos; Crystal Miller; James Siuty; Jill Kleczko; Leah Price; Grace Jeschke; Rona Weinberg; Titiksha Basu; Heike L Pahl; Attilio Orazi; Vesna Najfeld; Roberto Marchioli; Judith D Goldberg; Lewis R Silverman; Ronald Hoffman
Journal:  Leuk Lymphoma       Date:  2015-02-20

Review 3.  The promise of Janus kinase inhibitors in the treatment of hematological malignancies.

Authors:  Emilee Senkevitch; Scott Durum
Journal:  Cytokine       Date:  2016-10-27       Impact factor: 3.861

4.  Quantification of clonal hematopoiesis in polycythemia vera.

Authors:  Udo Siebolts; Murat Ates; Rüdiger Spitz; Jürgen Thiele; Claudia Wickenhauser
Journal:  Virchows Arch       Date:  2005-08-19       Impact factor: 4.064

5.  JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis.

Authors:  Amandeep Salhotra; Thein H Oo
Journal:  Indian J Hematol Blood Transfus       Date:  2012-12-18       Impact factor: 0.900

Review 6.  Clinical potential of pacritinib in the treatment of myelofibrosis.

Authors:  Ana B Duenas-Perez; Adam J Mead
Journal:  Ther Adv Hematol       Date:  2015-08

7.  JAK2 and Beyond: Mutational Study of JAK2V617 in Myeloproliferative Disorders and Haematological Malignancies in Kashmiri population.

Authors:  Nidda Syeed
Journal:  Asian Pac J Cancer Prev       Date:  2019-12-01

8.  Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms.

Authors:  Michelle Maccarini Barcelos; Maria Cláudia Santos-Silva
Journal:  Rev Bras Hematol Hemoter       Date:  2011
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.